Therefore, combined treatment with EZH2 and MEK1/2 inhibitors may provide a novel promising therapeutic strategy for NRAS-mutated and wild-type melanomas, as these types of melanomas are resistant to BRAF inhibitors (Terranova et al., 2021). Here, BRAF is linked to melanoma.